Scinai Immunotherapeutics
SCNI
5 hedge funds and large institutions have $495K invested in Scinai Immunotherapeutics in 2015 Q2 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$372K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$77.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.12K |
| 5 |
Citigroup
New York
|
+$3.3K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $391K | +$372K | +790 | New |
|
|
VKH
2
Virtu KCG Holdings
New York
| $82K | +$77.7K | +165 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $13K | +$12.2K | +26 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6K | +$6.12K | +13 | New |
|
|
5
Citigroup
New York
| $3K | +$3.3K | +7 | New |
|
SCNI Hedge Fund Activity: Q2 2015 in Review
5 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2015, worth a combined $495K.
Buyers outnumbered sellers: 5 funds opened new SCNI positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $372K.
- 5 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $495K of Scinai Immunotherapeutics stock for Q2 2015.
- 5 funds opened new Scinai Immunotherapeutics positions in Q2 2015 and 0 closed out, a net change of +5 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2015 was Jane Street, an estimated $372K added.
Based on aggregated 13F filings for Q2 2015.